However, the rate drops to 77% for triple‐negative [estrogen receptor negative (ER−), progesterone receptor negative (PR−), and human epidermal growth factor receptor 2 negative (HER2−)] breast cancer [3], which accounts for 10–15% of the total diagnosed breast cancer [4]. Here, ERBB2 is linked to breast carcinoma.